MX2023006768A - Metodos de identificacion de un tumor sensible al tratamiento con talazoparib y metodos de tratamiento del mismo. - Google Patents
Metodos de identificacion de un tumor sensible al tratamiento con talazoparib y metodos de tratamiento del mismo.Info
- Publication number
- MX2023006768A MX2023006768A MX2023006768A MX2023006768A MX2023006768A MX 2023006768 A MX2023006768 A MX 2023006768A MX 2023006768 A MX2023006768 A MX 2023006768A MX 2023006768 A MX2023006768 A MX 2023006768A MX 2023006768 A MX2023006768 A MX 2023006768A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- talazoparib
- homologous recombination
- identifying
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 title abstract 4
- 229950004550 talazoparib Drugs 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000006801 homologous recombination Effects 0.000 abstract 4
- 238000002744 homologous recombination Methods 0.000 abstract 4
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 3
- 230000035772 mutation Effects 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 230000007812 deficiency Effects 0.000 abstract 2
- 210000004602 germ cell Anatomy 0.000 abstract 2
- 230000037361 pathway Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108700020463 BRCA1 Proteins 0.000 abstract 1
- 102000036365 BRCA1 Human genes 0.000 abstract 1
- 101150072950 BRCA1 gene Proteins 0.000 abstract 1
- 108700020462 BRCA2 Proteins 0.000 abstract 1
- 102000052609 BRCA2 Human genes 0.000 abstract 1
- 101150008921 Brca2 gene Proteins 0.000 abstract 1
- 238000001574 biopsy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención se refiere a un método de identificación de un tumor metastásico que se ha determinado que presenta una mutación en los genes de la vía de recombinación homóloga, que es sensible al tratamiento con talazoparib, o una sal farmacéuticamente aceptable del mismo, y a métodos de tratamiento del mismo, que comprenden a) la determinación de una puntuación de deficiencia de recombinación homóloga a partir de una biopsia del tumor metastásico; y b) administrar talazoparib, o una sal farmacéuticamente aceptable del mismo, si la puntuación de deficiencia de recombinación homóloga es de al menos el 33%, en donde la mutación no es BRCA1 de línea germinal o BRCA2 de línea germinal. La presente invención también se refiere a un método de selección de un sujeto que se ha determinado que tiene un tumor metastásico con una mutación en los genes de la vía de recombinación homóloga, para su tratamiento con talazoparib, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063122453P | 2020-12-07 | 2020-12-07 | |
PCT/IB2021/061372 WO2022123427A1 (en) | 2020-12-07 | 2021-12-06 | Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023006768A true MX2023006768A (es) | 2023-06-19 |
Family
ID=79025076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023006768A MX2023006768A (es) | 2020-12-07 | 2021-12-06 | Metodos de identificacion de un tumor sensible al tratamiento con talazoparib y metodos de tratamiento del mismo. |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240052423A1 (es) |
EP (1) | EP4256088A1 (es) |
JP (1) | JP2023551968A (es) |
KR (1) | KR20230118597A (es) |
CN (1) | CN116802321A (es) |
CA (1) | CA3203814A1 (es) |
MX (1) | MX2023006768A (es) |
WO (1) | WO2022123427A1 (es) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0917119B1 (pt) | 2008-08-06 | 2021-07-13 | Medivation Technologies, Inc. | Composto, composição farmacêutica, uso dos mesmos e seu processo de fabricação |
CA2787844C (en) | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
CA2788114C (en) | 2010-02-08 | 2018-11-06 | Biomarin Pharmaceutical Inc. | Processes of synthesizing dihydropyridophthalazinone derivatives |
KR20210028747A (ko) | 2010-10-21 | 2021-03-12 | 메디베이션 테크놀로지즈 엘엘씨 | 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염 |
US20160280691A1 (en) | 2013-11-07 | 2016-09-29 | Biomarin Pharmaceutical Inc. | Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes |
SG11201700734RA (en) | 2014-07-31 | 2017-02-27 | Medivation Technologies Inc | Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
KR20180100546A (ko) | 2015-10-26 | 2018-09-11 | 메디베이션 테크놀로지즈 엘엘씨 | Parp 저해제를 이용한 소-세포성 폐암의 치료 방법 |
TW201929902A (zh) * | 2017-12-27 | 2019-08-01 | 美商提薩羅有限公司 | 治療癌症之方法 |
-
2021
- 2021-12-06 KR KR1020237022426A patent/KR20230118597A/ko active Search and Examination
- 2021-12-06 US US18/265,656 patent/US20240052423A1/en active Pending
- 2021-12-06 JP JP2023534087A patent/JP2023551968A/ja active Pending
- 2021-12-06 MX MX2023006768A patent/MX2023006768A/es unknown
- 2021-12-06 WO PCT/IB2021/061372 patent/WO2022123427A1/en active Application Filing
- 2021-12-06 EP EP21831108.2A patent/EP4256088A1/en active Pending
- 2021-12-06 CA CA3203814A patent/CA3203814A1/en active Pending
- 2021-12-06 CN CN202180093132.1A patent/CN116802321A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN116802321A (zh) | 2023-09-22 |
JP2023551968A (ja) | 2023-12-13 |
CA3203814A1 (en) | 2022-06-16 |
KR20230118597A (ko) | 2023-08-11 |
US20240052423A1 (en) | 2024-02-15 |
WO2022123427A1 (en) | 2022-06-16 |
EP4256088A1 (en) | 2023-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Little | Genomic instability and radiation | |
Roberts et al. | Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions | |
Mendoza et al. | The biology of retinoblastoma | |
Brody et al. | State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer | |
Curia et al. | MUTYH: Not just polyposis | |
Manenti et al. | Genetic mapping of lung cancer modifier loci specifically affecting tumor initiation and progression | |
Dunwell et al. | Frequent epigenetic inactivation of the SLIT2 gene in chronic and acute lymphocytic leukemia | |
Qureshi et al. | Correlation between selected XRCC2, XRCC3 and RAD51 gene polymorphisms and primary breast cancer in women in Pakistan | |
JP2018510884A5 (es) | ||
WO2021243280A3 (en) | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 | |
ATE488529T1 (de) | Zusammensetzungen und verfahren zur behandlung von tumoren | |
WO2003032813A3 (en) | Methods for the treatment of carcinoma | |
Taylor et al. | Loss-of-function mutations in the splicing factor ZRSR2 are common in blastic plasmacytoid dendritic cell neoplasm and have male predominance | |
MX2023006768A (es) | Metodos de identificacion de un tumor sensible al tratamiento con talazoparib y metodos de tratamiento del mismo. | |
Liu et al. | ALK and MYCN: when two oncogenes are better than one | |
Tschaharganeh et al. | Coordinated tumor suppression by chromosome 8p | |
TW200512198A (en) | 5-arylpyrimidines as anticancer agents | |
de Carvalho Fraga et al. | Angiotensin-converting enzymes (ACE and ACE2) as potential targets for malignant epithelial neoplasia: review and bioinformatics analyses focused in oral squamous cell carcinoma | |
Noë et al. | Pancreatic cancer pathology viewed in the light of evolution | |
WO2000015666A3 (en) | Compositions and methods for the treatment of tumors | |
Hosseini-Asl et al. | Decrease in gastric cancer susceptibility by MTHFR C677T polymorphism in Ardabil Province, Iran | |
DE50211672D1 (de) | Urokinase-inhibitoren | |
Fontebasso et al. | Pediatric brain tumors: genomics and epigenomics pave the way | |
ÖZEN et al. | Combined germline variations of thrombophilic genes promote genesis of lung cancer | |
Song et al. | Transduction effect of antisense K-ras on malignant phenotypes in gastric cancer cells |